“We had that question before, when we only had Enhertu and [Trodelvy]. Now we have three drugs.” When a patient stops responding to one ADC, it’s not always clear if they developed ...

AstraZeneca and Daiichi Sankyo were clearly excited by data from a trial pitting their HER2 antibody-drug conjugate (ADC) Enhertu against Roche's rival Kadcyla when they reported top-line results ...

Seagen claims Enhertu (trastuzumab deruxtecan) – an antibody-drug conjugate (ADC) targeting HER2 – infringes a patient it holds (No. 10,808,039) covering ADCs that include auristatin compounds ...

BB-1701 has survived Eisai’s decision not to option the HER2-directed antibody-drug conjugate. | BB-1701 has survived Eisai’s ...

Enhertu is a HER2-directed antibody-drug conjugate (ADC). Enhertu consists of a HER2 monoclonal antibody linked to multiple topoisomerase 1 inhibitor payloads, including the exatecan derivative DXd, ...

Antibody-drug conjugates (ADCs) are new drugs that combine a monoclonal antibody with a chemotherapy drug. They can specifically target cancer cells to deliver potent chemotherapy drugs.

Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan ... The trial compared the safety and efficacy of the antibody drug conjugate (ADC) to ramucirumab and paclitaxel in individuals ...

Enhertu is a combination of a chemotherapy drug and targeted therapy. This type of therapy differs from immunotherapy. Doctors prescribe Enhertu for certain types of breast, lung, and other ...

AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a randomized clinical trial in second-line metastatic stomach cancer ...

But unlike Enhertu, it carries more ... “Multi-payload ADCs have the potential to enable the targeted delivery of rational drug combinations to cancer cells, and may provide significantly ...

The European Union's health regulator on Friday backed AstraZeneca and Daiichi Sankyo's drug Enhertu as a breast cancer treatment for patients who received endocrine therapy but are not suitable for ...